Recent Changes in the Treatment Landscape of Acute Myeloid Leukemia

July 23, 2018
Daniel A. Pollyea, MD, MS

Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia. Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.

Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia (AML). Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.

There are many exciting advances that are both here now and on the horizon, Pollyea notes. Some of these advancements include targeted therapies based on protein expression. The key is to target the patient’s immune system so that the patient can kill the tumor themselves, Pollyea explains.